Pharma major Venus Remedies Limited announced on Saturday that it has received marketing authorisation from the Saudi Food and Drug Authority (SFDA) for speciality oncology therapy -- Plerixafor. According to reports from Business Standard, this marks the first marketing authorisation the company secured for Plerixafor anywhere in the world. The approval represents a significant regulatory milestone for the company's strategic shift toward differentiated, high-value therapies in regulated international markets, enabling the company to commercialize Plerixafor 24mg/1.2ml in Saudi Arabia through its established international business network.
Plerixafor is described as a hematopoietic stem cell mobiliser used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise stem cells into peripheral blood for collection and autologous transplantation. As reported by Business Standard, it is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant. Saransh Chaudhary, President, Global Critical Care at Venus Remedies Limited, emphasised that this approval positions the company in therapy classes with clinical complexity and regulatory rigour that create durable demand. The therapy is widely used in haemato-oncology, particularly for patients suffering from multiple myeloma and non-Hodgkin lymphoma undergoing stem cell transplantation procedures.
According to Business Standard, Aditi K Chaudhary, President, International Business at Venus Remedies Limited, highlighted that Saudi Arabia is the most important commercial market in the GCC for speciality oncology. The Saudi Arabian pharmaceutical market is projected to grow from USD 12.1 billion in 2026 to USD 17.1 billion by 2033, at a CAGR of 5 per cent, driven by rising chronic disease prevalence and healthcare investment under Vision 2030. The GCC stem cell therapy market was estimated at USD 1.2 billion in 2024, with Saudi Arabia, the UAE, and Qatar as principal markets, witnessing increasing demand led by Saudi Arabia, the UAE, and Qatar. The company will focus on tertiary oncology and transplant centers to commercialize the therapy.
As reported by Business Standard, Chaudhary stated that this approval provides a direct platform in Saudi Arabia to build hospital partnerships and anchor further speciality launches across the region. The company views this as reinforcing India's role as a credible supplier of complex injectables to demanding healthcare systems. Saransh Chaudhary, President, Global Critical Care, emphasised that Saudi Arabia represents an ideal launch market due to its expanding oncology and transplant infrastructure and its position as the largest pharmaceutical market in the GCC region. The regulatory approval demonstrates both regulatory and commercial execution capabilities in demanding markets like Saudi Arabia, where regulatory and commercial work are tightly linked.
